Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
Quintanilha JCF, Kelly WK, Innocenti F. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. Pharmacogenomics J. 2024 Jul 12; 24(4):22.
-
Patel JN, Jiang C, Owzar K, Hertz DL, Wang J, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
-
DesJarlais AM, Miller R, Ali AS, Niazi MZ, Cappelli L, Glass J, Farrell CJ, Shi W. Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment. Chin Clin Oncol. 2023 Dec; 12(6):69.
-
Patel SN. Pulmonary Hypertension and Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity-Is There a Link? JAMA Ophthalmol. 2022 11 01; 140(11):1094-1095.
-
Singh N, Temin S, Baker S, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. J Clin Oncol. 2022 10 01; 40(28):3323-3343.
-
Patel SN, Mokhashi N, Peck TJ, Cai LZ, Salabati M, Soares RR, Hinkle J, Chaudhary V, Kuriyan AE, Cohen MN, Hsu J, Garg SJ. Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review. Curr Eye Res. 2022 09; 47(9):1288-1293.
-
Durrani AF, Zhou Y, Musch DC, Demirci H. Treatment of Choroidal Hemangioma with Photodynamic Therapy and Bevacizumab. Ophthalmol Retina. 2022 06; 6(6):533-535.
-
Nanji K, Sarohia GS, Kennedy K, Ceyhan T, McKechnie T, Phillips M, Devji T, Thabane L, Kaiser P, Sarraf D, Garg SJ, Sivaprasad S, Wykoff CC, Bakri SJ, Sheidow T, Bhandari M, Chaudhary V. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2022 05; 129(5):498-508.
-
Nanji K, Khan M, Khalid MF, Xie JS, Sarohia GS, Phillips M, Thabane L, Garg SJ, Kaiser P, Sivaprasad S, Wykoff CC, Chaudhary V. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022 Sep; 100(6):e1199-e1208.
-
Matsunaga DR, Salabati M, Obeid A, Wibbelsman TD, Wu C, Mahmoudzadeh R, Ojalvo I, Bilello J, Sivalingam A, Ho AC, Chiang A, Hsu J. Outcomes of Eyes With Diabetic Macular Edema That Are Lost to Follow-up After Anti-Vascular Endothelial Growth Factor Therapy. Am J Ophthalmol. 2022 01; 233:1-7.